Biogen pauses or cancels most R&D programs from its $5.6B Apellis buyout and lays off staff, keeping its focus on Empaveli and Syfovre.
June 25, 2026 08:50 PM EDT
DealsR&D
After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work
Kyle LaHucik
Biotech Correspondent
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease…
Biogen pays up to $1B for secretive San Diego biotech RayThera, gaining three undisclosed anti-inflammatory candidates to expand…
Biogen leans on newly acquired Apellis' Empaveli and Syfovre to offset Leqembi's disappointing Alzheimer's sales ahead of Q2…
The companies didn’t specify the drugs Biogen is acquiring in the deal, though patents Raythera secured provide important clues.
Apogee details its $10.9B AbbVie buyout, the UK launches a drug-pricing pilot, and Brii shares Phase 2b HBV vaccine data.
BioCryst is shutting down internal drug discovery and closing its Birmingham, AL research site, cutting 2026 opex guidance to…
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic
